[1]
Huoponen, S.; Blom, M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS One, 2015, 10(12), e0145087.
[2]
Joensuu, J.T.; Huoponen, S.; Aaltonen, K.J.; Konttinen, Y.T.; Nordström, D.; Blom, M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One, 2015, 10(3), e0119683.
[3]
Zhang, W.; Islam, N.; Ma, C.; Anis, A.H. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics, 2015, 33(4), 327-340.
[4]
Laires, P.A.; Exposto, F.; Mesquita, R.; Martins, A.P.; Cunha-Miranda, L.; Fonseca, J.E. Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur. J. Health Econ., 2013, 14(6), 875-885.
[5]
Putrik, P.; Ramiro, S.; Hifinger, M.; Keszei, A.P.; Hmamouchi, I.; Dougados, M.; Gossec, L.; Boonen, A. In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. Ann. Rheum. Dis., 2016, 75(4), 715-720.
[6]
Putrik, P.; Ramiro, S.; Kvien, T.K.; Sokka, T.; Pavlova, M.; Uhlig, T.; Boonen, A. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis., 2014, 73(1), 198-206.
[7]
Putrik, P.; Ramiro, S.; Kvien, T.K.; Sokka, T.; Uhlig, T.; Boonen, A. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann. Rheum. Dis., 2014, 73(11), 2010-2021.
[8]
Rencz, F.; Péntek, M.; Bortlik, M.; Zagorowicz, E.; Hlavaty, T.; Śliwczyński, A.; Diculescu, M.M.; Kupcinskas, L.; Gecse, K.B.; Gulácsi, L.; Lakatos, P.L. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J. Gastroenterol., 2015, 21(6), 1728-1737.
[9]
Rencz, F.; Kemény, L.; Gajdácsi, J.Z.; Owczarek, W.; Arenberger, P.; Tiplica, G.S.; Stanimirović, A.; Niewada, M.; Petrova, G.; Marinov, L.T.; Kazandhieva, J.; Péntek, M.; Brodszky, V.; Gulácsi, L. Use of biologics for psoriasis in Central and Eastern European countries. J. Eur. Acad. Dermatol. Venereol., 2015, 29(11), 2222-2230.
[10]
Péntek, M.; Poór, G.; Wiland, P.; Olejárová, M.; Brzosko, M.; Codreanu, C.; Brodszky, N.; Gulácsi, L. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur. J. Health Econ., 2014, 15(Suppl. 1), S35-S43.
[11]
Dretzke, J.; Edlin, R.; Round, J.; Connock, M.; Hulme, C.; Czeczot, J.; Fry-Smith, A.; McCabe, C.; Meads, C. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol. Assess., 2011, 15(6), 1-244.
[12]
Boncz, I.; Sebestyén, A. Financial deficits in the health services of the UK and Hungary. Lancet, 2006, 368(9539), 917-918.
[13]
Dörner, T.; Strand, V.; Castañeda-Hernández, G.; Ferraccioli, G.; Isaacs, J.D.; Kvien, T.K.; Martin-Mola, E.; Mittendorf, T.; Smolen, J.S.; Burmester, G.R. The role of biosimilars in the treatment of rheumatic diseases. Ann. Rheum. Dis., 2013, 72(3), 322-328.
[14]
Dörner, T.; Strand, V.; Cornes, P.; Gonçalves, J.; Gulácsi, L.; Kay, J.; Kvien, T.K.; Smolen, J.; Tanaka, Y.; Burmester, G.R. The changing landscape of biosimilars in rheumatology. Ann. Rheum. Dis., 2016, 75(6), 974-982.
[15]
Vezér, B.; Buzás, Z.; Sebeszta, M.; Zrubka, Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr. Med. Res. Opin., 2016, 32(5), 829-834.
[16]
Fiorino, G.; Fazio, M.; Danese, S. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile? Expert Rev. Clin. Immunol., 2016, 12(4), 361-363.
[17]
Reinisch, W.; Louis, E.; Danese, S. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Rev. Gastroenterol. Hepatol., 2015, 9(Suppl. 1), 17-26.
[18]
Nikiphorou, E.; Kautiainen, H.; Hannonen, P.; Asikainen, J.; Kokko, A.; Rannio, T.; Sokka, T. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin. Biol. Ther., 2015, 15(12), 1677-1683.
[19]
Strand, V.; Cronstein, B. Biosimilars: how similar? Intern. Med. J., 2014, 44(3), 218-223.
[20]
Mendes de Abreu, M.; Strand, V.; Levy, R.A.; Araujo, D.V. Putting the value into biosimilar decision making: the judgment value criteria. Autoimmun. Rev., 2014, 13(6), 678-684.
[21]
Yoo, D.H.; Hrycaj, P.; Miranda, P.; Ramiterre, E.; Piotrowski, M.; Shevchuk, S.; Kovalenko, V.; Prodanovic, N.; Abello-Banfi, M.; Gutierrez-Ureña, S.; Morales-Olazabal, L.; Tee, M.; Jimenez, R.; Zamani, O.; Lee, S.J.; Kim, H.; Park, W.; Müller-Ladner, U. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis., 2013, 72(10), 1613-1620.
[22]
Park, W.; Hrycaj, P.; Jeka, S.; Kovalenko, V.; Lysenko, G.; Miranda, P.; Mikazane, H.; Gutierrez-Ureña, S.; Lim, M.; Lee, Y.A.; Lee, S.J.; Kim, H.; Yoo, D.H.; Braun, J. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis., 2013, 72(10), 1605-1612.
[23]
Baji, P.; Péntek, M.; Czirják, L.; Szekanecz, Z.; Nagy, G.; Gulácsi, L.; Brodszky, V. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur. J. Health Econ., 2014, 15(Suppl. 1), S53-S64.
[24]
Baji, P.; Péntek, M.; Szántó, S.; Géher, P.; Gulácsi, L.; Balogh, O.; Brodszky, V. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur. J. Health Econ., 2014, 15(Suppl. 1), S45-S52.
[25]
Takeuchi, T.; Yamanaka, H.; Tanaka, Y.; Sakurai, T.; Saito, K.; Ohtsubo, H.; Lee, S.J.; Nambu, Y. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod. Rheumatol., 2015, 25(6), 817-824.
[26]
Farkas, K.; Rutka, M.; Bálint, A.; Nagy, F.; Bor, R.; Milassin, Á.; Szepes, Z.; Molnár, T. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis - experiences from a single center. Expert Opin. Biol. Ther., 2015, 15(9), 1257-1262.
[27]
Gecse, K.B.; Lovász, B.D.; Farkas, K.; Banai, J.; Bene, L.; Gasztonyi, B.; Golovics, P.A.; Kristóf, T.; Lakatos, L.; Csontos, A.A.; Juhász, M.; Nagy, F.; Palatka, K.; Papp, M.; Patai, Á.; Lakner, L.; Salamon, Á.; Szamosi, T.; Szepes, Z.; Tóth, G.T.; Vincze, Á.; Szalay, B.; Molnár, T.; Lakatos, P.L. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: A prospective, multicentre, nationwide cohort. J. Crohn’s Colitis, 2016, 10(2), 133-140.
[28]
Jung, Y.S.; Park, D.I.; Kim, Y.H.; Lee, J.H.; Seo, P.J.; Cheon, J.H.; Kang, H.W.; Kim, J.W. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J. Gastroenterol. Hepatol., 2015, 30(12), 1705-1712.
[32]
Ebbers, H.C. Biosimilars: in support of extrapolation of indications. J. Crohn’s Colitis, 2014, 8(5), 431-435.
[33]
Gulácsi, L.; Rencz, F.; Poór, G.; Szekanecz, Z.; Brodszky, V.; Baji, P.; Péntek, M. Patients’ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Ann. Rheum. Dis., 2016, 75(5), 942-943.
[34]
Sokka, T.; Kautiainen, H.; Pincus, T.; Toloza, S.; da Rocha Castelar Pinheiro, G.; Lazovskis, J.; Hetland, M.L.; Peets, T.; Immonen, K.; Maillefert, J.F.; Drosos, A.A.; Alten, R.; Pohl, C.; Rojkovich, B.; Bresnihan, B.; Minnock, P.; Cazzato, M.; Bombardieri, S.; Rexhepi, S.; Rexhepi, M.; Andersone, D.; Stropuviene, S.; Huisman, M.; Sierakowski, S.; Karateev, D.; Skakic, V.; Naranjo, A.; Baecklund, E.; Henrohn, D.; Gogus, F.; Badsha, H.; Mofti, A.; Taylor, P.; McClinton, C.; Yazici, Y. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann. Rheum. Dis., 2009, 68(11), 1666-1672.
[35]
Gulácsi, L.; Brodszky, V.; Baji, P.; Kim, H.; Kim, S.Y.; Cho, Y.Y.; Péntek, M. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev. Clin. Immunol., 2015, 11(Suppl. 1), S43-S52.
[36]
Farfan-Portet, M.I.; Gerkens, S.; Lepage-Nefkens, I.; Vinck, I.; Hulstaert, F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur. J. Health Econ., 2014, 15(3), 223-228.
[39]
Neumann, D.; Jabłecka, A. Reimbursement of biosimilars in Poland: is there a link to health technology assessment? Expert Rev. Pharmacoecon. Outcomes Res., 2016, 16(6), 781-792.
[40]
Grabowski, H.; Guha, R.; Salgado, M. Biosimilar competition: lessons from Europe. Nat. Rev. Drug Discov., 2014, 13(2), 99-100.
[41]
Daubenfeld, T.; Dassow, J.; Keßler, M.; Schulze, J. Understanding the market dynamics of biosimilars. J. Bus. Chem., 2016, 13(1), 33-46.
[42]
Bocquet, F.; Fusier, I.; Cordonnier, A.; Lechat, P.; Paubel, P. Budget impact analysis of implementing tenders between the branded infliximab and its biosimilars in the public hospitals of paris. Value Health, 2015, 18(7), A639.
[43]
Rencz, F.; Gulácsi, L.; Péntek, M.; Gecse, K.B.; Dignass, A.; Halfvarson, J.; Gomollón, F.; Baji, P.; Peyrin-Biroulet, L.; Lakatos, P.L.; Brodszky, V. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev. Pharmacoecon. Outcomes Res., 2017, 17(6), 597-606.
[44]
Brodszky, V.; Baji, P.; Balogh, O.; Péntek, M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur. J. Health Econ., 2014, 15(Suppl. 1), S65-S71.
[45]
Brodszky, V.; Rencz, F.; Péntek, M.; Baji, P.; Lakatos, P.L.; Gulácsi, L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev. Pharmacoecon. Outcomes Res., 2016, 16(1), 119-125.
[46]
Kim, S.; Hong, J.A.; Kudrin, A. 10th Congress of European Crohn’s and Colitis Organisation (ECCO), February 18-21, 20152015, Vol. 66, pp. S512-S512.
[47]
Kim, S.C.; Choi, N.K.; Lee, J.; Kwon, K.E.; Eddings, W.; Sung, Y.K.; Song, H.J.; Kesselheim, A.S.; Solomon, D.H. Uptake of the first biosimilar infliximab since its approval in south korea. Arthritis Rheumatol., 2015, 67, 1615-1616.
[48]
Jha, A.; Upton, A.; Dunlop, W.C.; Akehurst, R. Remsima(R) for the treatment of autoimmune diseases in five european countries. Adv. Ther., 2015, 32(8), 742-756.
[49]
Lucioni, C.; Mazzi, S.; Caporali, R. Budget impact analysis of infliximab biosimilar: The Italian scenery. Global & Regional Health Technology Assessment, 2015, 2(2), 78-88.
[50]
McCarthy, G.; Ebel Bitoun, C.; Guy, H. Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health, 2013, 16(7), A558.
[52]
Ruff, L.; Rezk, M.F.; Uhlig, T.; Gommers, J.W. Budget impact analysis of an etanercept biosimilar for the treatment of all licensed etanercept indications for adults in europe. Value Health, 2015, 18(7), A639.
[53]
Ruff, L.; Rezk, M.F.; Uhlig, T.; Gommers, J.W. Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis in europe. Value Health, 2015, 18(7), A639.
[56]
Claxton, K.; Martin, S.; Soares, M.; Rice, N.; Spackman, E.; Hinde, S.; Devlin, N.; Smith, P.C.; Sculpher, M. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol. Assess., 2015, 19(14), 1-503. v-vi.
[57]
Gulácsi, L.; Rotar, A.M.; Niewada, M.; Löblová, O.; Rencz, F.; Petrova, G.; Boncz, I.; Klazinga, N.S. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur. J. Health Econ., 2014, 15(Suppl. 1), S13-S25.
[58]
Siegel, J.E.; Torrance, G.W.; Russell, L.B.; Luce, B.R.; Weinstein, M.C.; Gold, M.R. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in health and medicine. Pharmacoeconomics, 1997, 11(2), 159-168.
[59]
Cleemput, I.; Neyt, M.; Thiry, N.; De Laet, C.; Leys, M. Threshold values for cost-effectiveness in healthcare Health
Technology Assessment (HTA). Brussels: Belgian Health
Care Knowledge Centre (KCE); 2008. CE reports 100C
(D/2008/10.273/96).
[60]
Cleemput, I.; Neyt, M.; Thiry, N.; De Laet, C.; Leys, M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int. J. Technol. Assess. Health Care, 2011, 27(1), 71-76.
[61]
Neumann, P.J.; Cohen, J.T.; Weinstein, M.C. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N. Engl. J. Med., 2014, 371(9), 796-797.
[62]
Nanavaty, M.; Kaura, S.; Mwamburi, M.; Gogate, A.; Proach, J.; Nyandege, A.; Khan, Z.M. The use of incremental cost-effectiveness ratio thresholds in health technology assessment decisions. J. Clin. Pathways, 2015, 1(1), 29-36.
[64]
Ananthakrishnan, A.N.; Hur, C.; Juillerat, P.; Korzenik, J.R. Strategies for the prevention of postoperative recurrence in Crohn’s disease: results of a decision analysis. Am. J. Gastroenterol., 2011, 106(11), 2009-2017.
[65]
Ananthakrishnan, A.N.; Hur, C.; Korzenik, J.R. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysis. Dig. Dis. Sci., 2012, 57(2), 472-480.
[66]
Arseneau, K.O.; Cohn, S.M.; Cominelli, F.; Connors, A.F., Jr Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology, 2001, 120(7), 1640-1656.
[67]
Assasi, N.; Blackhouse, G.; Xie, F.; Gaebel, K.; Marshall, J.; Irvine, E.J.; Giacomini, M.; Robertson, D.; Campbell, K.; Hopkins, R.; Goeree, R. Anti-TNF-α drugs for refractory
inflammatory bowel disease: Clinical- and costeffectiveness
analyses [Technology report number 120]. Ottawa:
Canadian Agency for Drugs and Technologies in
Health; 2009.
[68]
Blackhouse, G.; Assasi, N.; Xie, F.; Marshall, J.; Irvine, E.J.; Gaebel, K.; Campbell, K.; Hopkins, R.; O’Reilly, D.; Tarride, J.E.; Goeree, R. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn’s disease. J. Crohn’s Colitis, 2012, 6(1), 77-85.
[69]
Bodger, K.; Kikuchi, T.; Hughes, D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther., 2009, 30(3), 265-274.
[70]
Clark, W.; Raftery, J.; Song, F.; Barton, P.; Cummins, C.; Fry-Smith, A.; Burls, A. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol. Assess., 2003, 7(3), 1-67.
[71]
Doherty, G.A.; Miksad, R.A.; Cheifetz, A.S.; Moss, A.C. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease. Inflamm. Bowel Dis., 2012, 18(9), 1608-1616.
[72]
Jaisson-Hot, I.; Flourié, B.; Descos, L.; Colin, C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int. J. Technol. Assess. Health Care, 2004, 20(3), 274-279.
[73]
Kaplan, G.G.; Hur, C.; Korzenik, J.; Sands, B.E. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment. Pharmacol. Ther., 2007, 26(11-12), 1509-1520.
[74]
Lindsay, J.; Punekar, Y.S.; Morris, J.; Chung-Faye, G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment. Pharmacol. Ther., 2008, 28(1), 76-87.
[75]
Loftus, E.V., Jr; Johnson, S.J.; Yu, A.P.; Wu, E.Q.; Chao, J.; Mulani, P.M. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease. Eur. J. Gastroenterol. Hepatol., 2009, 21(11), 1302-1309.
[76]
Marchetti, M.; Liberato, N.L.; Di Sabatino, A.; Corazza, G.R. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease. Eur. J. Health Econ., 2013, 14(6), 853-861.
[77]
Marshall, J.; Blackhouse, G.; Goeree, R.; Brazier, N.; Irvine, E.; Faulkner, L.; Dipchand, C.; O’Brien, B. Infliximab
for the treatment of Crohn's disease: A systematic review
and cost-utility analysis. Ottawa: Canadian Coordinating
Office for Health Technology Assessment (CCOHTA);
2002. Technology report no 24,, 2002.
[78]
Saito, S.; Shimizu, U.; Nan, Z.; Mandai, N.; Yokoyama, J.; Terajima, K.; Akazawa, K. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn’s disease: A cost-effectiveness analysis. J. Crohn’s Colitis, 2013, 7(2), 167-174.
[79]
Tang, D.H.; Armstrong, E.P.; Lee, J.K. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn’s disease. Pharmacotherapy, 2012, 32(6), 515-526.
[80]
Yu, A.P.; Johnson, S.; Wang, S.T.; Atanasov, P.; Tang, J.; Wu, E.; Chao, J.; Mulani, P.M. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics, 2009, 27(7), 609-621.
[81]
Saito, S.; Shimizu, U.; Nan, Z.; Yokoyama, J.; Watanabe, M.; Terajima, K.; Akazawa, K. A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease. Health, 2014, 6(1), 107-114.
[82]
Rafia, R.; Scope, A.; Harnan, S.; Stevens, J.; Stevenson, M.; Sutton, A.; Dickinson, K.; Parkes, M.; Mayberry, J.; Lobo, A. Vedolizumab for the treatment of adults with moderately to severely active Crohn’s disease: A Single Technology Appraisal. School of Health and Related Research (ScHARR); Shef-field, 2014.
[84]
Essat, M.; Tappenden, P.; Ren, S.; Bessey, A.; Archer, R.; Wong, R.; Lobo, A.; Hoque, S. Vedolizumab for the treatment of adults with moderate-to-severe active ulcerative colitis: An evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics, 2016, 34(3), 245-257.
[85]
Essat, M.; Tappenden, P.; Ren, S.; Bessey, A.; Archer, R.; Wong, R.; Lobo, A.; Hoque, S. Vedolizumab for the treatment of adults with moderate-to-severe active ulcerative colitis: An evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics, 2016, 34(3), 245-257.
[86]
Deiana, S.; Gabbani, T.; Annese, V. Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World J. Gastroenterol., 2017, 23(2), 197-203.
[87]
Danese, S.; Fiorino, G.; Michetti, P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization [ECCO] members: An updated survey. J. Crohn’s Colitis, 2016, 10(11), 1362-1365.
[88]
Peyrin-Biroulet, L.; Lönnfors, S.; Roblin, X.; Danese, S.; Avedano, L. Patient perspectives on biosimilars: A Survey by the european federation of crohn’s and ulcerative colitis associations. J. Crohn’s Colitis, 2017, 11(1), 128-133.
[89]
Danese, S.; Fiorino, G.; Raine, T.; Ferrante, M.; Kemp, K.; Kierkus, J.; Lakatos, P.L.; Mantzaris, G.; van der Woude, J.; Panes, J.; Peyrin-Biroulet, L. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J. Crohn’s Colitis, 2017, 11(1), 26-34.
[90]
Grabowski, D.; Henderson, B.; Lam, D.; Keystone, E.C.; Thorne, C.; Jamal, S.; Pope, J.; Haraoui, B.; Lin, D.; Revers, L. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin. Rheumatol., 2015, 34(8), 1427-1433.
[91]
Derbyshire, M. Update on US state legislation on biosimilars substitution. GaBi J., 2015, 4(2), 95-97.
[93]
Declerck, P.; Simoens, S. A European perspective on the market accessibility of biosimilars. Biosimilars, 2012, 2, 33-40.
[95]
Gulácsi, L.; Péntek, M. HTA in central and eastern European countries; the 2001: A Space Odyssey and efficiency gain. Eur. J. Health Econ., 2014, 15(7), 675-680.
[96]
Ben-Horin, S.; Vande Casteele, N.; Schreiber, S.; Lakatos, P.L. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin. Gastroenterol. Hepatol., 2016, 14(12), 1685-1696.
[97]
Baji, P.; Gulácsi, L.; Lovász, B.D.; Golovics, P.A.; Brodszky, V.; Péntek, M.; Rencz, F.; Lakatos, P.L. Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scand. J. Gastroenterol., 2016, 51(1), 22-27.
[98]
Baji, P.; Gulácsi, L.; Golovics, P.A.; Lovász, B.D.; Péntek, M.; Brodszky, V.; Rencz, F.; Lakatos, P.L. Perceived risks contra benefits of using biosimilar drugs in ulcerative colitis: Discrete choice experiment among gastroenterologists. Value Health Reg. Issues, 2016, 10, 85-90.
[99]
Danese, S.; Fiorino, G.; Michetti, P. 11th Congress of European Crohn’s and Colitis Organisation (ECCO), March 16-19, 2016Amsterdam, The Netherlands2016.
[100]
Danese, S.; Gomollon, F. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J. Crohn’s Colitis, 2013, 7(7), 586-589.
[101]
Wilkins, A.R.; Venkat, M.V.; Brown, A.S.; Dong, J.P.; Ran, N.A.; Hirsch, J.S.; Close, K.L. Patient perspectives on biosimilar insulin. J. Diabetes Sci. Technol., 2014, 8(1), 23-25.
